Virios Therapeutics Inc. (VIRI)
0.15
0.01 (8.77%)
At close: Oct 08, 2024, 8:00 PM
8.77% (1D)
| Bid | n/a |
| Market Cap | 206.5K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.68M |
| EPS (ttm) | -5.75 |
| PE Ratio (ttm) | -0.026956521739130435 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | n/a |
| Volume | 42,356,733 |
| Avg. Volume (20D) | 87,787 |
| Open | 0.21 |
| Previous Close | 0.14 |
| Day's Range | 0.14 - 0.21 |
| 52-Week Range | 0.14 - 26.00 |
| Beta | 1.58 |
About VIRI
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, atten...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 17, 2020
Employees 4
Stock Exchange NASDAQ
Ticker Symbol VIRI
Website https://www.virios.com
Analyst Forecast
According to 2 analyst ratings, the average rating for VIRI stock is "Hold." The 12-month stock price forecast is $15, which is an increase of 9577.42% from the latest price.
Stock Forecasts9 months ago
+6.84%
Virios Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
11 months ago
-43.85%
Virios Therapeutics shares are trading lower after the company priced a $1.7 million pubic offering of 8.5 million shares of common stock at $0.20 per share.